

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
11 April 2024 (11.04.2024)



(10) International Publication Number
WO 2024/077246 A1

(51) International Patent Classification:

A61K 39/395 (2006.01) A61K 47/12 (2006.01)
A61K 47/26 (2006.01) A61K 9/08 (2006.01)

(21) International Application Number:

PCT/US2023/076250

(22) International Filing Date:

06 October 2023 (06.10.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/414,206 07 October 2022 (07.10.2022) US

(71) Applicant: ANNEXON, INC. [US/US]; 1400 Sierra Point
Parkway, Building C, 2nd Floor, Brisbane, CA 94005 (US).

(72) Inventors: OLIYAI, Cecilia; c/o Annexon, Inc., 1400 Sierra
Point Parkway, Building C, 2nd Floor, Brisbane, CA
94005 (US). THAI, Khoi; c/o Annexon, Inc., 1400 Sierra
Point Parkway, Building C, 2nd Floor, Brisbane, CA 94005
(US).

(74) Agent: HALSTEAD, David, P. et al.; Foley Hoag LLP, 155
Seaport Boulevard, Boston, MA 02210-2600 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(54) Title: FORMULATIONS FOR ANTI-C1Q ANTIBODIES

(57) Abstract: The present disclosure is generally directed to pharmaceutical compositions comprising anti-C1q antibodies and methods of making and using such compositions. In certain embodiments, such compositions are high concentration anti-C1q antibody formulations that exhibit low viscosity and high stability and can therefore be conveniently delivered to subjects in need thereof with reduced discomfort.



WO 2024/077246 A1